Phaseline

Targets › CTGF

CTGF (CCN family member 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology; next expected readout Jan 2032.

Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. (UniProt, P29279)

Open in Phaseline: the race on CTGF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Neurotech PharmaceuticalsNT-501/revakinagene taroretcel-lwey
Surgically implanted intraocular device expressing recombinant human ciliary neurotrophic
CTGFPhase 4Macular Telangiectasia Type 2 (MacTel)Jan 2032

Conditions

Macular Telangiectasia Type 2 (MacTel) (1)

Modalities

other (1)

Companies

Neurotech Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.